ÜBAG MVZ Onkologische Kooperation Harz
Welcome,         Profile    Billing    Logout  
 0 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zahn, Mark-Oliver
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Recruiting
3
430
Europe
Concomitant coaching
AIO-Studien-gGmbH, Pfizer, Crolll Gmbh
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
01/24
07/24
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
09/23
09/28
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Chronic Lymphoid Leukemia
09/27
09/27
CLL-Frail, NCT04883749: Efficacy of Acalabrutinib in Very Old or Frail Patients with Treatment-naïve or Relapsed/Refractory CLL

Active, not recruiting
2
53
Europe
Acalabrutinib, Calquence, ACP-196
German CLL Study Group
Chronic Lymphoid Leukemia
05/25
05/25
NCT03474744 / 2017-003150-16: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Active, not recruiting
2
36
Europe
Copanlisib, Aliqopa, Rituximab, Truxima
Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer
Marginal Zone Lymphoma
06/24
12/29
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
08/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
Kambach, Timo
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Completed
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
08/24
08/24
PLATON, NCT05489250: The Network

Active, not recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32

Download Options